Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: July 25, 2006
Last updated: November 10, 2011
Last verified: November 2011
Persistence of seroprotective antibody concentrations & immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine

Condition Intervention Phase
Hepatitis B
Biological: hepatitis B vaccine
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B & Immune Response to a Hepatitis B Challenge Dose in Healthy Children 7 to 9 Yrs Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Anti-HBs antibody concentration

Secondary Outcome Measures:
  • Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.
  • Sol & unsol symptoms after HBV vaccination, SAEs

Estimated Enrollment: 350
Study Start Date: July 2006

Ages Eligible for Study:   7 Years to 9 Years   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A male or female aged 7 to 9 years at the time of study entry .
  • Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine or a total of 4 doses of HBV vaccine in previous vaccination studies.
  • Evidence of previous hepatitis B booster vaccination or disease since administration of the fourth dose of DTPa-HBV-IPV/Hib or HBV vaccine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00356564

GSK Investigational Site
Ettenheim, Baden-Wuerttemberg, Germany, 77955
GSK Investigational Site
Kehl, Baden-Wuerttemberg, Germany, 77694
GSK Investigational Site
Oberkirch, Baden-Wuerttemberg, Germany, 77704
GSK Investigational Site
Offenburg, Baden-Wuerttemberg, Germany, 77654
GSK Investigational Site
Aichach, Bayern, Germany, 86551
GSK Investigational Site
Bobingen, Bayern, Germany, 86399
GSK Investigational Site
Erding, Bayern, Germany, 85435
GSK Investigational Site
Kaufering, Bayern, Germany, 86916
GSK Investigational Site
Kempten, Bayern, Germany, 87435
GSK Investigational Site
Landsberg, Bayern, Germany, 86899
GSK Investigational Site
Lohr, Bayern, Germany, 97816
GSK Investigational Site
Muenchen, Bayern, Germany, 81241
GSK Investigational Site
Muenchen, Bayern, Germany, 81243
GSK Investigational Site
Noerdlingen, Bayern, Germany, 86720
GSK Investigational Site
Pegnitz, Bayern, Germany, 91257
GSK Investigational Site
Tutzing, Bayern, Germany, 82327
GSK Investigational Site
Weilheim, Bayern, Germany, 82362
GSK Investigational Site
Marburg/Lahn, Hessen, Germany, 35039
GSK Investigational Site
Salzgitter, Niedersachsen, Germany, 38226
GSK Investigational Site
Erkrath, Nordrhein-Westfalen, Germany, 40699
GSK Investigational Site
Krefeld, Nordrhein-Westfalen, Germany, 47798
GSK Investigational Site
Willich, Nordrhein-Westfalen, Germany, 47877
GSK Investigational Site
Bad Sobernheim, Rheinland-Pfalz, Germany, 55566
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
GSK Investigational Site
Schoeneberg - Kuebelberg, Rheinland-Pfalz, Germany, 66901
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54290
GSK Investigational Site
Bischofswerda, Sachsen, Germany, 01877
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Altenholz, Schleswig-Holstein, Germany, 24161
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24937
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24944
GSK Investigational Site
Husum, Schleswig-Holstein, Germany, 25813
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany, 24161
GSK Investigational Site
Niebuell, Schleswig-Holstein, Germany, 25899
GSK Investigational Site
Lobenstein, Thueringen, Germany, 07356
GSK Investigational Site
Rudolstadt, Thueringen, Germany, 07407
GSK Investigational Site
Berlin, Germany, 10249
GSK Investigational Site
Berlin, Germany, 10999
GSK Investigational Site
Berlin, Germany, 13355
GSK Investigational Site
Berlin, Germany, 13507
GSK Investigational Site
Hamburg, Germany, 22415
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Zinke M et al. Immune memory against hepatitis B persists in 7-9 year olds previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Abstract presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Graz, Austria, 13-17 May 2008.
Zinke M et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Abstract presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Graz, Austria, 13-17 May 2008.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00356564     History of Changes
Other Study ID Numbers: 106744 
Study First Received: July 25, 2006
Last Updated: November 10, 2011
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by GlaxoSmithKline:
Prophylaxis for hepatitis B disease

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Immunologic Factors
Physiological Effects of Drugs processed this record on September 30, 2016